No Cover Image

Journal article 106 views 331 downloads

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma / Michele Maio; Patrick Schöffski; Matteo S. Carlino; Céleste Lebbé; Grant McArthur; Paolo A. Ascierto; Gregory A. Daniels; Georgina V. Long; Lars Bastholt; Jasmine I. Rizzo; Agnes Balogh; Andriy Moshyk; Massimo Guidoboni; John Haanen; Andrew Hill; F. Stephen Hodi; David Hogg; Michael Smylie; Pier F. Ferrucci; Reinhard Dummer; John Wagstaff; Dirk Schadendorf; C. Lance Cowey; Christopher D. Lao; Piotr Rutkowski; Jean-Jacques Grob; Rene Gonzalez; Vanna Chiarion-Sileni; James Larkin; Ivan Márquez-Rodas; Jedd D. Wolchok

New England Journal of Medicine, Volume: 381, Issue: 16, Pages: 1535 - 1546

Swansea University Author: John, Wagstaff

  • 52612.pdf

    PDF | Version of Record

    Copyright © (2019) Massachusetts Medical Society. Reprinted with permission

    Download (345.88KB)

Check full text

DOI (Published version): 10.1056/nejmoa1910836

Abstract

945 patients with inoperable stage III or stage IV melanoma were randomised to ipilimumab plus nivolumab (ipi/nivo)(314), nivolumab (nivo) (316) or ipilimumab (Ipilimumab) (315). The minimum follow up from randomisation of the last patient was 60 months. Objective responses were seen in 58% of Ipili...

Full description

Published in: New England Journal of Medicine
ISSN: 0028-4793 1533-4406
Published: Massachusetts Medical Society 2019
Online Access: Check full text

URI: https://cronfa.swan.ac.uk/Record/cronfa52612
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract: 945 patients with inoperable stage III or stage IV melanoma were randomised to ipilimumab plus nivolumab (ipi/nivo)(314), nivolumab (nivo) (316) or ipilimumab (Ipilimumab) (315). The minimum follow up from randomisation of the last patient was 60 months. Objective responses were seen in 58% of Ipilimumab/nivo, 45% of nivo and 19% of Ipilimumab patients. Complete responses were seen in 22% (Ipilimumab/nivo), 19% (nivo) and 6% (Ipi) patients. Overall survival (OS) at five years was 52% (Ipilimumab/nivo), 44% (nivo) and 26% (Ipi). In patients with and without bras mutations the OS at five years was 60 & 48% (Ipilimumab/nivo), 46 & 43% (nivo) and 30 & 25% (Ipi) respectively. OS curves were flat beyond three years indicating that these treatments lead to sustained long term survival of these patients.
Keywords: Melanoma, ipilimumab, nivolumab, overall survival
Issue: 16
Start Page: 1535
End Page: 1546